title: Oral absorption of CGS-20625, an insoluble drug, in dogs and man.
abstract: Oral bioavailability of highly water-insoluble drugs is often quite limited and variable, requiring the development of improved formulations. Animal models are an essential aspect of the design and testing of such formulations designed to improve absorption in man. The present report compares the absorption of CGS-20625, an insoluble drug, in dog and man after oral administration of the drug as a powder, a solid dispersion capsule, and after gastric and duodenal administration in PEG 400 solution. CGS-20625 powder (20 mg) given orally exhibited slow, delayed absorption in both dog and man, with a Cmax of 0.26 +/- 0.07 microgram/ml at Tmax of 3 hr in dog, and 0.01 +/- 0.004 microgram/ml at 2 hr in man. Administration of CGS-20625 in PEG 400 solution improved absorption in dog and man, with a Cmax of 1.2 +/- 0.10 microgram/ml at Tmax of 0.25 hr in dog, and a Cmax of 0.10 +/- 0.04 microgram/ml at 0.5 hr in man. Tmax after administration of the hard gelatin capsule formulation was 0.9 and 1.0 hr in dog and man, with Cmax of 0.89 +/- 0.16 and 0.052 +/- 0.014 microgram/ml, respectively. Absolute bioavailability of CGS-20625 powder in the dog was 0.67 +/- 0.21, whereas the bioavailabilities of the powder and the capsule relative to the PEG 400 solution were 0.84 and 1.1, respectively, in dog, and 0.41 and 0.85 respectively, in man. No significant benefits of duodenal administration were observed. Plasma levels were approximately 10-fold greater and oral clearance was approximately 5-fold less in the dog than in man. Furthermore, pharmacokinetic data were less variable and relative bioavailability was greater in dogs than in humans. Physiological factors in the gastrointestinal tract or greater first-pass metabolism in man may account for these species differences. The relative rate and extent of CGS-20625 absorption were similar between dog and man, in the order of powder < capsule < PEG 400 solution. In addition, in vivo absorption rates in both species reflect in vitro dissolution differences between the powder and the capsule. These data strongly support the use of the dog as a model for developing improved formulations of CGS-20625. Further investigation of the dog as a model to evaluate insoluble drug absorption is warranted.
authors.affiliation: Pharmaceuticals Division, Ciba-Geigy Corporation, Ardsley, New York 10502, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Hirschberg
authors.forename: R L
authors.initials: RL
authors.lastname: Oberle
authors.forename: M
authors.initials: M
authors.lastname: Ortiz
authors.forename: H
authors.initials: H
authors.lastname: Lau
authors.forename: M
authors.initials: M
authors.lastname: Markowska
mesh_terms: D000042:Absorption; D000284:Administration, Oral; D000328:Adult; D000818:Animals; D014151:Anti-Anxiety Agents / Q000493:pharmacokinetics*; D001682:Biological Availability; D004285:Dogs; D005260:Female; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D011720:Pyrazoles / Q000493:pharmacokinetics*
chemical_list: D014151:Anti-Anxiety Agents; D011720:Pyrazoles; C054732:CGS 20625